SLC38A2 and breast carcinoma: Knockdown of SLC38A2 in breast cancer cells regulates mTORC1 signaling, reduces glutamine consumption in breast cancer cell lines, sensitizes cells to low-glutamine conditions, and increases ROS production (Morotti et al., 2021).